Human umbilical cord-derived mesenchymal stem cell therapy (Shenzhen Hornetcorn Bio-technology)

人脐带间充质干细胞疗法（合一康生物）

Report date: 2023/01/12 15:47:50

Base Information

Drug NameHuman umbilical cord-derived mesenchymal stem cell therapy (Shenzhen Hornetcorn Bio-technology)
Drug Alias NameCB-MSCs
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsFibrosisLung DiseasesOsteoarthritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Hornetcorn Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Hornetcorn Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsFibrosisLung DiseasesOsteoarthritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A